Doxorubicin encapsulated nanocells - EnGeneIC

Drug Profile

Doxorubicin encapsulated nanocells - EnGeneIC

Alternative Names: EGFREDVDox; Doxorubicin packaged EDV™ nanocells - EnGeneIC; Doxorubicin-loaded EDV nanocells; EGFR(V)-EDV-Dox; EnGeneIC Delivery Vehicle™; EnGeneIC Dream Vector™; VEDVDox

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EnGeneIC
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action Immunostimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Solid tumours
  • Preclinical Brain cancer

Most Recent Events

  • 09 Aug 2017 Phase-I clinical trials in Solid tumours (Treatment-naive) in Australia (IV) (EnGeneIC pipeline, August 2017)
  • 02 Mar 2017 Doxorubicin encapsulated nanocells receives Orphan Drug status for Glioblastoma in USA
  • 25 Oct 2016 Phase-I clinical trials in Glioblastoma (Recurrent, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02766699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top